Form 4 for ADMA ADMA BIOLOGICS, INC.

Accepted 2024-09-11 00:00:00 ET · period of report 2024-09-09 · accession 0001140361-24-040872 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2024-09-11	2024-09-09	ADMA	Guiheen Lawrence P.	Dir	M - OptEx	$10.80	+9,000	162.9K	+6%	+$97.2K
D	2024-09-11	2024-09-09	ADMA	Guiheen Lawrence P.	Dir	S - Sale+OE	$18.47	-9,000	153.9K	-6%	-$166.2K
D	2024-09-11	2024-09-09	ADMA	Guiheen Lawrence P.	Dir	M - OptEx	$10.80	-9,000	0	-100%	-$97.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-09-09	M	A	9,000	$10.80	162,941	D	—	—
2	Common	Common Stock	2024-09-09	S	D	9,000	$18.47	153,941	D	—	—	(F1) The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $18.465 to $18.47. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. (F2) Includes, as of the transaction date, (i) 12,020 restricted stock units granted on February 26, 2024, which will vest fully on February 26, 2025, subject to the Reporting Person's continued service as of such vesting date; and (ii) 141,921 shares of common stock owned by the Reporting Person.
3	Derivative	Common Stock	2024-09-09	M	D	9,000	$10.80	0	D	$10.80 · — to 2025-01-30	9,000 Common Stock	(F5) The Reporting Person is exercising these options due, in part, to their near-term expiration date. (F4) These options were granted on January 30, 2015 and vested in twenty-four equal monthly installments, becoming fully vested on January 30, 2017.